TAFNAT 25MG

About

TAFNAT 25MG contains Tenofovir Alafenamide (TAF), a novel prodrug of tenofovir, which is an antiviral medication. TAF is a nucleotide reverse transcriptase inhibitor (NRTI) primarily used in the treatment of chronic hepatitis B virus (HBV) infection and human immunodeficiency virus type 1 (HIV-1) infection. Its unique formulation allows for more efficient delivery of tenofovir to target cells, resulting in lower systemic drug exposure compared to its predecessor, tenofovir disoproxil fumarate (TDF). This improved pharmacokinetic profile translates into enhanced renal and bone safety, making it a preferred option for many patients requiring long-term antiviral therapy.

TAF works by interfering with the reverse transcriptase enzyme, which is essential for the replication of both HBV and HIV. By inhibiting this enzyme, TAF effectively reduces viral load and helps to prevent disease progression. Its efficacy, coupled with a favorable safety profile, makes it a cornerstone in current treatment regimens for these chronic viral infections. Adherence to the prescribed regimen is crucial for optimal therapeutic outcomes and to minimize the development of drug resistance.

Uses

• Treatment of chronic hepatitis B virus (HBV) infection.
• Part of combination therapy for human immunodeficiency virus type 1 (HIV-1) infection.
• Pre-exposure prophylaxis (PrEP) for HIV-1 infection.
• Used in adults and pediatric patients (specific age criteria apply).

Directions For Use

Take orally once daily with food. Swallow the tablet whole.

Benefits

• Highly effective against HBV and HIV.
• Improved renal safety profile compared to TDF.
• Improved bone safety profile compared to TDF.
• Convenient once-daily dosing.
• High barrier to drug resistance.
• Generally well-tolerated.

Side Effects

• Nausea
• Diarrhea
• Headache
• Abdominal pain
• Fatigue
• Flatulence
• Skin rash
• Elevated liver enzymes
• Lactic acidosis (rare)
• Renal impairment (less common than TDF)
• Decreased bone mineral density (less common than TDF)
• Vomiting

Safety Measures

• Alcohol - Limit alcohol consumption, as it can worsen liver disease, particularly in patients with chronic hepatitis B infection.
• Pregnancy - Generally considered safe for use during pregnancy, but consult a physician to weigh benefits against potential risks.
• Breastfeeding - Consult a physician. It is unknown if Tenofovir Alafenamide is excreted in breast milk, and potential for infant exposure should be considered.
• Liver - Use with caution in patients with decompensated liver disease. Liver function should be monitored regularly.
• Kidney - Monitor renal function, especially in patients with pre-existing kidney impairment, although TAF generally has a better renal safety profile than TDF.
• Lung - No specific lung-related safety concerns are commonly associated with Tenofovir Alafenamide.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.